Psomagen（A950200）株式概要Psomagen, Inc.は、オミックスソリューションと受託ラボサービスを提供している。 詳細A950200 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性5/6配当金0/6リスク分析過去5年間で収益は年間4.8%減少しました。 意味のある時価総額がありません ( ₩52B )すべてのリスクチェックを見るA950200 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₩Current Price₩2.73k19.8% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-6b61b2016201920222025202620282031Revenue ₩60.7bEarnings ₩11.2bAdvancedSet Fair ValueView all narrativesPsomagen, Inc. 競合他社QuantaMatrixSymbol: KOSDAQ:A317690Market cap: ₩52.9bIMB DxSymbol: KOSDAQ:A461030Market cap: ₩54.3bTegoScienceSymbol: KOSDAQ:A191420Market cap: ₩57.6bEyeGeneSymbol: KOSDAQ:A185490Market cap: ₩59.8b価格と性能株価の高値、安値、推移の概要Psomagen過去の株価現在の株価₩2,725.0052週高値₩4,665.0052週安値₩2,550.00ベータ-0.231ヶ月の変化-14.58%3ヶ月変化-18.66%1年変化-29.50%3年間の変化-63.42%5年間の変化-80.04%IPOからの変化-81.95%最新ニュースNew Risk • May 30New major risk - Revenue and earnings growthEarnings have declined by 4.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.8% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩58.2b market cap, or US$38.6m).お知らせ • Mar 17Psomagen, Inc., Annual General Meeting, Mar 31, 2026Psomagen, Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 406, teheran-ro, gangnam-gu, seoul South Korea分析記事 • Jan 30Is Psomagen (KOSDAQ:950200) Weighed On By Its Debt Load?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Board Change • Jul 15Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Mi-Rye Kim was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Mar 18Psomagen, Inc., Annual General Meeting, Mar 31, 2025Psomagen, Inc., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 406, teheran-ro, gangnam-gu, seoul South Korea分析記事 • Aug 28Companies Like Psomagen (KOSDAQ:950200) Are In A Position To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although...最新情報をもっと見るRecent updatesNew Risk • May 30New major risk - Revenue and earnings growthEarnings have declined by 4.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.8% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩58.2b market cap, or US$38.6m).お知らせ • Mar 17Psomagen, Inc., Annual General Meeting, Mar 31, 2026Psomagen, Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 406, teheran-ro, gangnam-gu, seoul South Korea分析記事 • Jan 30Is Psomagen (KOSDAQ:950200) Weighed On By Its Debt Load?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Board Change • Jul 15Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Mi-Rye Kim was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Mar 18Psomagen, Inc., Annual General Meeting, Mar 31, 2025Psomagen, Inc., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 406, teheran-ro, gangnam-gu, seoul South Korea分析記事 • Aug 28Companies Like Psomagen (KOSDAQ:950200) Are In A Position To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although...Buy Or Sell Opportunity • Aug 05Now 31% undervalued after recent price dropOver the last 90 days, the stock has fallen 17% to ₩4,020. The fair value is estimated to be ₩5,796, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 20% over the last year. Earnings per share has declined by 1,037%.分析記事 • Jul 05A Look At The Fair Value Of Psomagen, Inc. (KOSDAQ:950200)Key Insights The projected fair value for Psomagen is ₩5,079 based on 2 Stage Free Cash Flow to Equity Psomagen's...Buy Or Sell Opportunity • Jul 01Now 23% undervalued after recent price dropOver the last 90 days, the stock has fallen 24% to ₩3,940. The fair value is estimated to be ₩5,109, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 20% over the last year. Earnings per share has declined by 1,037%.Buy Or Sell Opportunity • Jun 19Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 34% to ₩3,995. The fair value is estimated to be ₩5,093, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 20% over the last year. Earnings per share has declined by 1,037%.New Risk • Mar 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Market cap is less than US$100m (₩103.9b market cap, or US$77.6m).New Risk • Jan 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩100.0b market cap, or US$74.3m).お知らせ • Sep 13Psomagen Announces the Launch of Spatial Biology Services for 10X Genomics Xenium™?Multiomics CRO Psomagen announced the launch of Spatial Biology services for 10X Genomics Xenium™?. This platform is reshaping spatial biology, enabling researchers worldwide to analyze the interplay of genes and proteins within their native tissue context. This marks a pivotal moment in the scientific community's access to spatial genomics. Key Features of Psomagen's Xenium Service: Precision: Xenium's spatial profiling provides unprecedented precision and sensitivity. Pinpoint gene expression patterns within single cells in context, enabling a deeper understanding of cellular heterogeneity and function. Multiomics Approach: Psomagen integrates various omics platforms, including genomics, transcriptomics, and proteomics. Researchers can analyze the molecular landscape of tissues and the interplay between molecular components. Quality: Psomagen's stringent quality controls are built into every project. Psomagen is a 10X Genomics and Olink Certified Service Provider with CAP and CLIA accreditations. Expertise: Psomagen's experienced scientists and bioinformaticians ensure researchers receive comprehensive support throughout their projects.New Risk • Jul 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩131.7b (US$100.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩131.7b market cap, or US$100.0m).Reported Earnings • Nov 20Third quarter 2022 earnings released: EPS: ₩51.00 (vs ₩90.00 loss in 3Q 2021)Third quarter 2022 results: EPS: ₩51.00 (up from ₩90.00 loss in 3Q 2021). Revenue: ₩12.4b (up 87% from 3Q 2021). Net income: ₩1.03b (up ₩2.67b from 3Q 2021). Profit margin: 8.3% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue.お知らせ • Feb 24Psomagen, Inc. Expands Precision Genomics Capabilities with 10x Genomics’ Single Cell Sequencing TechnologiesPsomagen, Inc. expands its next-generation sequencing capabilities to include end-to-end single cell sequencing (SCS) services. These services, which include gene expression and single cell immune profiling, are powered by the Chromium platform and Next GEM-based technology from 10x Genomics, a life science technology company building products to interrogate, understand, and master biology. SCS is being used to help scientists better understand the mechanisms of infection and immune response at the level of an individual cell. That knowledge is important because it helps learn how to better prevent and treat diseases like COVID-19, cancer, Alzheimer’s, and more. Psomagen’s SCS team is building on the company’s long-standing genomics expertise, handling the entire study workflow for its clients — from sample clean up and quality control to library preparation, sequencing, and analysis of complex cell populations. In less than three weeks, Psomagen’s clients have results and the detailed molecular insights they need to answer even the most complicated research questions.Is New 90 Day High Low • Feb 20New 90-day low: ₩12,000The company is down 47% from its price of ₩22,500 on 20 November 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period.Is New 90 Day High Low • Feb 04New 90-day low: ₩12,450The company is down 14% from its price of ₩14,450 on 06 November 2020. The South Korean market is up 27% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 11% over the same period.分析記事 • Jan 13We're Not Very Worried About Psomagen's (KOSDAQ:950200) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although...Is New 90 Day High Low • Nov 13New 90-day high: ₩18,100The company is up 10.0% from its price of ₩16,450 on 14 August 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period.Is New 90 Day High Low • Oct 15New 90-day low: ₩13,300The company is down 33% from its price of ₩20,000 on 17 July 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 3.0% over the same period.株主還元A950200KR BiotechsKR 市場7D-4.2%0.2%10.0%1Y-29.5%9.1%179.9%株主還元を見る業界別リターン: A950200過去 1 年間で9.1 % の収益を上げたKR Biotechs業界を下回りました。リターン対市場: A950200は、過去 1 年間で179.9 % のリターンを上げたKR市場を下回りました。価格変動Is A950200's price volatile compared to industry and market?A950200 volatilityA950200 Average Weekly Movement6.6%Biotechs Industry Average Movement10.9%Market Average Movement8.8%10% most volatile stocks in KR Market16.2%10% least volatile stocks in KR Market4.5%安定した株価: A950200 、 KR市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: A950200の 週次ボラティリティ ( 7% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト200485Su Hongwww.psomagen.comオミックス・ソリューションと受託ラボ・サービスの提供。同社の研究サービスは、遺伝子の配列と発現の研究であるゲノミクス、細胞内のクロマチンアセンブリ、ヒストン修飾、DNA-タンパク質相互作用などのエピジェネティックな変化の研究であるエピゲノミクス、懸濁液、生物学的流体、組織、細胞集団の研究であるシングルセル分析で構成されている；遺伝子発現が生物の生物学に与える影響を解析するために使用される、シーケンシングによるRNAとその発現の研究であるトランスクリプトミクス、生物に発現するすべてのタンパク質（プロテオーム）の研究であるプロテオミクス。また、科学者のデータ解析を支援するソフトウェアツールとパイプラインであるバイオインフォマティクスや、臨床遺伝学的検査、全ゲノム、全エクソーム、サンガーシーケンスサービスも提供している。同社は以前Macrogen Corp.として知られていたが、2019年4月にPsomagen, Inc.に社名を変更した。Psomagen, Inc.は2004年に法人化され、デラウェア州ウィルミントンに本社を置いている。もっと見るPsomagen, Inc. 基礎のまとめPsomagen の収益と売上を時価総額と比較するとどうか。A950200 基礎統計学時価総額₩52.32b収益（TTM）-₩1.59b売上高(TTM)₩60.70b0.9xP/Sレシオ-33.0xPER（株価収益率A950200 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A950200 損益計算書（TTM）収益₩60.70b売上原価₩45.18b売上総利益₩15.52bその他の費用₩17.11b収益-₩1.59b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-82.55グロス・マージン25.57%純利益率-2.62%有利子負債／自己資本比率16.3%A950200 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/22 22:09終値2026/06/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Psomagen, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • May 30New major risk - Revenue and earnings growthEarnings have declined by 4.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.8% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩58.2b market cap, or US$38.6m).
お知らせ • Mar 17Psomagen, Inc., Annual General Meeting, Mar 31, 2026Psomagen, Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 406, teheran-ro, gangnam-gu, seoul South Korea
分析記事 • Jan 30Is Psomagen (KOSDAQ:950200) Weighed On By Its Debt Load?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Board Change • Jul 15Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Mi-Rye Kim was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 18Psomagen, Inc., Annual General Meeting, Mar 31, 2025Psomagen, Inc., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 406, teheran-ro, gangnam-gu, seoul South Korea
分析記事 • Aug 28Companies Like Psomagen (KOSDAQ:950200) Are In A Position To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although...
New Risk • May 30New major risk - Revenue and earnings growthEarnings have declined by 4.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.8% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩58.2b market cap, or US$38.6m).
お知らせ • Mar 17Psomagen, Inc., Annual General Meeting, Mar 31, 2026Psomagen, Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 406, teheran-ro, gangnam-gu, seoul South Korea
分析記事 • Jan 30Is Psomagen (KOSDAQ:950200) Weighed On By Its Debt Load?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Board Change • Jul 15Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Mi-Rye Kim was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 18Psomagen, Inc., Annual General Meeting, Mar 31, 2025Psomagen, Inc., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 406, teheran-ro, gangnam-gu, seoul South Korea
分析記事 • Aug 28Companies Like Psomagen (KOSDAQ:950200) Are In A Position To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Buy Or Sell Opportunity • Aug 05Now 31% undervalued after recent price dropOver the last 90 days, the stock has fallen 17% to ₩4,020. The fair value is estimated to be ₩5,796, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 20% over the last year. Earnings per share has declined by 1,037%.
分析記事 • Jul 05A Look At The Fair Value Of Psomagen, Inc. (KOSDAQ:950200)Key Insights The projected fair value for Psomagen is ₩5,079 based on 2 Stage Free Cash Flow to Equity Psomagen's...
Buy Or Sell Opportunity • Jul 01Now 23% undervalued after recent price dropOver the last 90 days, the stock has fallen 24% to ₩3,940. The fair value is estimated to be ₩5,109, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 20% over the last year. Earnings per share has declined by 1,037%.
Buy Or Sell Opportunity • Jun 19Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 34% to ₩3,995. The fair value is estimated to be ₩5,093, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 20% over the last year. Earnings per share has declined by 1,037%.
New Risk • Mar 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Market cap is less than US$100m (₩103.9b market cap, or US$77.6m).
New Risk • Jan 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩100.0b market cap, or US$74.3m).
お知らせ • Sep 13Psomagen Announces the Launch of Spatial Biology Services for 10X Genomics Xenium™?Multiomics CRO Psomagen announced the launch of Spatial Biology services for 10X Genomics Xenium™?. This platform is reshaping spatial biology, enabling researchers worldwide to analyze the interplay of genes and proteins within their native tissue context. This marks a pivotal moment in the scientific community's access to spatial genomics. Key Features of Psomagen's Xenium Service: Precision: Xenium's spatial profiling provides unprecedented precision and sensitivity. Pinpoint gene expression patterns within single cells in context, enabling a deeper understanding of cellular heterogeneity and function. Multiomics Approach: Psomagen integrates various omics platforms, including genomics, transcriptomics, and proteomics. Researchers can analyze the molecular landscape of tissues and the interplay between molecular components. Quality: Psomagen's stringent quality controls are built into every project. Psomagen is a 10X Genomics and Olink Certified Service Provider with CAP and CLIA accreditations. Expertise: Psomagen's experienced scientists and bioinformaticians ensure researchers receive comprehensive support throughout their projects.
New Risk • Jul 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩131.7b (US$100.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩131.7b market cap, or US$100.0m).
Reported Earnings • Nov 20Third quarter 2022 earnings released: EPS: ₩51.00 (vs ₩90.00 loss in 3Q 2021)Third quarter 2022 results: EPS: ₩51.00 (up from ₩90.00 loss in 3Q 2021). Revenue: ₩12.4b (up 87% from 3Q 2021). Net income: ₩1.03b (up ₩2.67b from 3Q 2021). Profit margin: 8.3% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue.
お知らせ • Feb 24Psomagen, Inc. Expands Precision Genomics Capabilities with 10x Genomics’ Single Cell Sequencing TechnologiesPsomagen, Inc. expands its next-generation sequencing capabilities to include end-to-end single cell sequencing (SCS) services. These services, which include gene expression and single cell immune profiling, are powered by the Chromium platform and Next GEM-based technology from 10x Genomics, a life science technology company building products to interrogate, understand, and master biology. SCS is being used to help scientists better understand the mechanisms of infection and immune response at the level of an individual cell. That knowledge is important because it helps learn how to better prevent and treat diseases like COVID-19, cancer, Alzheimer’s, and more. Psomagen’s SCS team is building on the company’s long-standing genomics expertise, handling the entire study workflow for its clients — from sample clean up and quality control to library preparation, sequencing, and analysis of complex cell populations. In less than three weeks, Psomagen’s clients have results and the detailed molecular insights they need to answer even the most complicated research questions.
Is New 90 Day High Low • Feb 20New 90-day low: ₩12,000The company is down 47% from its price of ₩22,500 on 20 November 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period.
Is New 90 Day High Low • Feb 04New 90-day low: ₩12,450The company is down 14% from its price of ₩14,450 on 06 November 2020. The South Korean market is up 27% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 11% over the same period.
分析記事 • Jan 13We're Not Very Worried About Psomagen's (KOSDAQ:950200) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although...
Is New 90 Day High Low • Nov 13New 90-day high: ₩18,100The company is up 10.0% from its price of ₩16,450 on 14 August 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Oct 15New 90-day low: ₩13,300The company is down 33% from its price of ₩20,000 on 17 July 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 3.0% over the same period.
